IX. Pharmaco-Economic Workshop/Webinar of Czech Myeloma Group
NOTICE: The validity of the information on this page has expired.
25.-26. 11. 2021
Thursday 25. 11. 2021
Advisory boards & CMG board
(The first part of the workshop is for invited physicians, second part for members of CMG board only)
(The first part of the workshop is for invited physicians, second part for members of CMG board only)
19.00 – 20.15
Advisory Board Takeda
salonek Dyje
20.30 – 23.30
Czech Myeloma Group Board
salonek Dyje
Friday 26. 11. 2021
Educational Workshops
08.00 – 09.00
Advisory Board (TBD)
09.15 – 10.15
New platform of RMG – update (CMG and IBA representatives)
10.30 – 12.00
Meeting of CMG board members and heads of regional hematology centers
12.00 – 13.00
Lunch
Pharmaco-economic Workshop
13.00
Welcome and Introduction
R. Hájek (Ostrava)
R. Hájek (Ostrava)
13.05 – 14.00
Register of Monoclonal Gammopathies (RMG) of CMG
Moderator: V. Maisnar (Hradec Králové)
V. Maisnar (Hradec Králové): RMG register update summary
J. Minařík (Olomouc): Ixazomib data set & RMG
V. Sandecká (Brno): Carfilzomib update & RMG
T. Jelínek (Ostrava): Daratumumab update & RMG
R. Hájek (Ostrava): Real Word Evidence & RMG plus MPE atlas - drugs availability across Europe and Czech Rep.
Moderator: V. Maisnar (Hradec Králové)
V. Maisnar (Hradec Králové): RMG register update summary
J. Minařík (Olomouc): Ixazomib data set & RMG
V. Sandecká (Brno): Carfilzomib update & RMG
T. Jelínek (Ostrava): Daratumumab update & RMG
R. Hájek (Ostrava): Real Word Evidence & RMG plus MPE atlas - drugs availability across Europe and Czech Rep.
14.00 – 14.45
The year 2022 – Priorities for Czech Republic
Moderator: J. Radocha (Hradec Králové)
T. Ševčíková (Ostrava) – NGS panel for MM
J. Radocha (Hradec Králové) – triplets that are needed in RRMM
T. Jelínek (Ostrava): Immunotherapy & immunomonitoring
T. Pika/R.Hájek (Olomouc): New guidelines & new drug for AL amyloidosis
M. Kaščák (Ostrava): New guidelines & new drug for Morbus Waldenström
Moderator: J. Radocha (Hradec Králové)
T. Ševčíková (Ostrava) – NGS panel for MM
J. Radocha (Hradec Králové) – triplets that are needed in RRMM
T. Jelínek (Ostrava): Immunotherapy & immunomonitoring
T. Pika/R.Hájek (Olomouc): New guidelines & new drug for AL amyloidosis
M. Kaščák (Ostrava): New guidelines & new drug for Morbus Waldenström
14.45 – 15.15
Discussion (representatives of SÚKL, Insurance companies, CHS and CMG)
15.15 – 15.30
Break
15.35 – 16.15
Up-date of academic clinical trials of CMG/EMN
Moderator: L.Pour (Brno)
A. Dorociaková (CMG office): EMN18 and EMN24 trials for NDMM – update
J. Radocha (Hradec Králové): EMN register of covid – 19 update
L. Pour (Brno): Clinical trials using bis-/trispecific monoclonal antibodies in Czech Rep
O. Šušol (Ostrava): Efficacy of anti-covid 19 vaccine in hematologic malignancies
Moderator: L.Pour (Brno)
A. Dorociaková (CMG office): EMN18 and EMN24 trials for NDMM – update
J. Radocha (Hradec Králové): EMN register of covid – 19 update
L. Pour (Brno): Clinical trials using bis-/trispecific monoclonal antibodies in Czech Rep
O. Šušol (Ostrava): Efficacy of anti-covid 19 vaccine in hematologic malignancies
16.15 – 16.30
Break
16.30 – 18.00
Meeting of CMG board members, CMG foundation members and heads of regional hematology centers
Moderator: I. Mareschová and R. Hájek
Moderator: I. Mareschová and R. Hájek
Friday 26. 11. 2019
13.05 – 17.00
In parallel with the workshop is running a Section of datamanagers and research nurses, dealing with the practical filling of the register RMG, news releases and discussion with the registry monitor.
Updated: 11. 11. 2021
